Filters: keyword is Receptors [Clear All Filters]
- 2008
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42. DOI
- 2007
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis,
Annu Rev Pharmacol Toxicol, vol. 47, pp. 357-400. DOI
- 2006
Naloxone reversal of buprenorphine-induced respiratory depression,
Anesthesiology, vol. 105, no. 1, pp. 51-7. DOI
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21. DOI
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics,
J Pharmacol Exp Ther, vol. 313, no. 3, pp. 1136-49. DOI
- 2003
Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action,
Neurosci Lett, vol. 343, no. 1, pp. 57-61. DOI
Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1251-7. DOI
- 2002
Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release,
Eur J Pharmacol, vol. 454, no. 2-3, pp. 177-82. DOI
Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan,
Eur J Pharmacol, vol. 445, no. 1-2, pp. 43-54. DOI
Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats,
J Pharmacol Exp Ther, vol. 303, no. 3, pp. 1130-7. DOI
Electroencephalography parameters as biomarkers: extrapolation from laboratory animals to humans,
Methods Find Exp Clin Pharmacol, vol. 24 Suppl D, pp. 63-4. DOI
- 2001
Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats,
Eur J Pharmacol, vol. 414, no. 2-3, pp. 233-43. DOI
- 2000
Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Application to a pharmacokinetic-pharmacodynamic study in rats,
J Chromatogr B Biomed Sci Appl, vol. 738, no. 1, pp. 67-73.
- 1999
Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat,
J Pharm Sci, vol. 88, no. 3, pp. 306-12. DOI
- 1997
Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling,
Int J Clin Pharmacol Ther, vol. 35, no. 10, pp. 442-6.
On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation,
J Pharmacol Toxicol Methods, vol. 38, no. 2, pp. 81-5. DOI
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo,
J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.
- 1996
Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect,
J Pharmacol Exp Ther, vol. 279, no. 2, pp. 803-12.
Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo,
Br J Pharmacol, vol. 118, no. 2, pp. 369-77.
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats,
Eur J Pharmacol, vol. 308, no. 3, pp. 311-4. DOI
Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo,
J Pharmacol Exp Ther, vol. 279, no. 3, pp. 1439-46.
- 1995
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor,
J Med Chem, vol. 38, no. 20, pp. 4000-6.
8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor,
Eur J Pharmacol, vol. 290, no. 3, pp. 189-99.
Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline,
Br J Pharmacol, vol. 115, no. 7, pp. 1253-9.


